Personalized medical treatment strategies for patients with chronic myeloid leukemia.

about

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q36118424

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@ast

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@en

type

Item

label

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@ast

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@en

prefLabel

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@ast

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@en

P1476

Personalized medical treatment strategies for patients with chronic myeloid leukemia.

@en

P2093

Catherine Burton

http://www.w3.org/2001/XMLSchema#string

David Marin

http://www.w3.org/2001/XMLSchema#string

Jane Apperley

http://www.w3.org/2001/XMLSchema#string

P2860

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Overriding imatinib resistance with a novel ABL kinase inhibitor

Homoharringtonine: history, current research, and future direction.

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

P304

343-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.5.2.343

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15877530

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia